New Study Suggests Common Sweetener May Hinder Cancer Treatment
Recent research indicates that a popular artificial sweetener, sucralose, may reduce the effectiveness of cancer treatments, particularly immunotherapy. The study, conducted by researchers from the University of Pittsburgh and the UPMC Hillman Cancer Center, reviewed cases involving 132 patients diagnosed with melanoma and non-small cell lung cancer.
All participants were receiving anti-PD1 treatment, a form of immunotherapy, either alone or alongside chemotherapy. They provided dietary information that included how much sucralose they consumed through diet sodas, low-calorie snacks, and sugar substitutes.
The findings revealed that patients who consumed higher amounts of sucralose experienced poorer treatment responses and lower survival rates. According to Diwakar Davar, a leading researcher and medical oncologist, the presence of sucralose seems to hinder the effectiveness of immunotherapy across various cancer types and treatments.
The implications of this research may lead to new dietary recommendations for cancer patients. It also suggests that developing prebiotics might help counteract the negative effects of high sucralose consumption, enhancing treatment outcomes.
Interestingly, the researchers found that supplements containing the amino acid arginine could potentially improve the effectiveness of immunotherapy for mice in a separate study. Abby Overacre, an assistant professor involved in the research, emphasized the difficulty of asking patients to change their diets drastically during treatment.
The study posits that sucralose may alter the gut microbiome, leading to decreased levels of arginine crucial for T-cell function in the immune response.
As the researchers plan to conduct further trials on arginine supplementation in cancer patients, they also intend to explore how other sugar alternatives might affect treatment efficacy. This research has received support from various health institutions and highlights the importance of personalized approaches in cancer care.
A spokesperson from the Calorie Control Council noted that dietary decisions for cancer patients should always be made in consultation with their healthcare teams.
While this study opens the door to new inquiries, it also points out the limitations of relying solely on animal studies and self-reported dietary habits from patients. More extensive research is necessary to fully understand the impact of sucralose on cancer treatments.
